Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
CMPS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
fool.com
1 hour ago
seekingalpha.com
4 hours ago
businesswire.com
6 hours ago
seekingalpha.com
14 hours ago
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.67
vs -0.43
Q4.23
N/A
-0.53
vs -0.73
Q1.24
N/A
-0.55
vs -0.57
Q2.24
N/A
-0.56
vs -0.62
Q3.24
N/A
-0.56
vs -0.67
Q4.24
N/A
-0.63
vs -0.53
Q1.25
N/A
-0.44
vs -0.55
Q2.25
N/A
-0.38
vs -0.56
Q3.25
N/A
-0.40
vs -0.56
Q4.25
N/A
-0.39
vs -0.63
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
3.7M vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-100%
NA vs 3.7M
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Return on Equity
QoQ
Q1.23
-15%
-0.15
vs -0.17
Q2.23
-17%
-0.17
vs -0.15
Q3.23
-13%
-0.13
vs -0.17
Q4.23
-15%
-0.15
vs -0.13
Q1.24
-14%
-0.14
vs -0.15
Q2.24
-17%
-0.17
vs -0.14
Q3.24
-20%
-0.20
vs -0.17
Q4.24
-28%
-0.28
vs -0.20
Q1.25
-9%
-0.09
vs -0.28
Q2.25
-24%
-0.24
vs -0.09
Institutionnal Ownership
QoQ
Q1.23
108
108
vs 115
-6%
Q2.23
105
105
vs 108
-3%
Q3.23
123
123
vs 105
17%
Q4.23
134
134
vs 123
9%
Q1.24
123
123
vs 134
-8%
Q2.24
131
131
vs 123
7%
Q3.24
140
140
vs 131
7%
Q4.24
136
136
vs 140
-3%
Q1.25
140
140
vs 136
3%
Q2.25
147
147
vs 140
5%
Quote Panel
Key Metrics
Forecast
2026-Revenue
-262%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
RBC Capital
initialisePrevious: Not converted
2024-07-22
Now: Outperform
Morgan Stanley
initialisePrevious: Not converted
2024-04-01
Now: Overweight
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.06 ( 1.19%)
Relative Strenght
18
Volume Buzz
-97%
Earning Acce
Yes
Dist 52w H.
32%Relative Strength
CMPS
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|